FDA approves atezolizumab plus chemotherapy for stage III dMMR colon cancer
A Cochrane review links drug-company promotion to less appropriate prescribing, the FDA approves atezolizumab for stage III dMMR colon cancer, and an early optogenetics trial restores some light sensitivity in retinitis pigmentosa.
FDA says its mifepristone safety review will run into 2027
Optogenetic gene therapy partially restores light sensitivity in advanced retinitis pigmentosa, the FDA says its mifepristone safety review will run into 2027, and WHO issues its first child obesity guideline.